v3.26.1
Supplemental Cash Flow Disclosures
12 Months Ended
Jan. 31, 2026
Supplemental Cash Flow Disclosures  
Supplemental Cash Flow Disclosures

13. Supplemental Cash Flow Disclosures

 

 

 

January 31,

2026

$

 

 

January 31,

2025

$

 

 

January 31,

2024

$

 

 

 

 

 

 

 

 

 

 

 

Supplemental disclosures:

 

 

 

 

 

 

 

 

 

Interest paid

 

 

6,660

 

 

 

31,817

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-cash investing and financing activities:

 

 

 

 

 

 

 

 

 

 

 

 

Common shares issued for settlement of amounts due to related parties and accounts payable

 

 

1,349,937

 

 

 

19,688

 

 

 

 

Common shares of MedMelior issued for settlement of amounts due to related parties

 

 

 

 

 

284,000

 

 

 

 

Brokers’ warrants granted as issue costs for convertible debentures

 

 

 

 

 

14,606

 

 

 

 

Common shares and share purchase warrants issued for conversion of debentures and accrued interest

 

 

619,691

 

 

 

702,180

 

 

 

 

Brokers’ warrants granted as share issue costs

 

 

 

 

 

 

 

 

45,371